Trelegy
Trelegy Ellipta is a triple-combination inhaled medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients requiring multiple therapies. It combines three active ingredients—an inhaled corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-agonist (vilanterol)—to reduce inflammation, relax airway muscles, and improve breathing. This once-daily inhaler is typically prescribed when single-agent or dual-therapy inhalers have not adequately controlled symptoms.
Trelegy is a once-daily triple-combination inhaler for COPD and asthma that uses three medications to reduce inflammation, open airways, and improve breathing in patients needing multiple therapies.
Key facts at a glance
- RxNorm
- 1945040
- Generic
- Trelegy
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Trelegy is indicated for the maintenance treatment of COPD (including chronic bronchitis and emphysema) and as a once-daily asthma maintenance treatment in patients 18 years and older who require an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-agonist.
Trelegy combines three mechanisms: fluticasone furoate reduces airway inflammation, umeclidinium blocks muscarinic receptors to prevent airway constriction, and vilanterol stimulates beta2-receptors to relax bronchial smooth muscle, resulting in improved airflow and symptom relief.
Trelegy is not for acute bronchospasm or sudden breathing problems; patients should carry a rescue inhaler. Common side effects include oral thrush, hoarseness, headache, and upper respiratory infections. It should not be used with other LABAs or LAMAs to avoid excess anticholinergic or bronchodilator effects. Patients should rinse their mouth after each use to reduce the risk of oral candidiasis.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy